Ultime notizie per Skye Bioscience (NASDAQ:SKYE) Azioni

Skye Bioscience

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience Inc

Skye Bioscience Inc Ordinary Shares

Skye Petroleum Inc

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $15.853 million which beat the analyst consensus estimate of $15.850 million by 0.02 percent. This is a 2.76 percent decrease over sales of $16.303 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

SOPH

Sophia Genetics Q3 2024 GAAP EPS $(0.28) Misses $(0.22) Estimate, Sales $15.853M Beat $15.850M Estimate

WIIM

Celanese shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it intends to temporarily reduce its quarterly dividend.

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Downgrades

Price Target

Analyst Ratings

CGNX

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Buybacks

Emerson Reveals Increased Return of Capital To Shareholders With Plans To Repurchase Approximately $2B Of Shares In FY25; Expecting $1B In Fiscal Q1

Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) released its Q3 earnings on Thursday, October 24, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Boyd Gaming beat estimated earnings by 10.0%, reporting an EPS of $1.52 versus an estimate of $1.38.
Revenue was up $58.08 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.09 in the last quarter, resulting in a 4.0% increase share price change the following day.
Here's a look at Boyd Gaming's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.49</td>
<td>1.57</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.58</td>
<td>1.51</td>
<td>1.66</td>
<td>1.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>912.95M</td>
<td>909.06M</td>
<td>958.74M</td>
<td>930.47M</td>
<td>879.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>961.25M</td>
<td>967.51M</td>
<td>960.52M</td>
<td>954.41M</td>
<td>903.16M</td>
</tr>
</tbody>
</table>

<h3>Competitors' Recent Earnings Updates</h3>
It's important to consider Boyd Gaming's numbers in relation to how its competitors, like PENN Entertainment, Golden Entertainment, and Inspired Entertainment, have been performing.
<ul>
<li>PENN Entertainment announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.26, PENN Entertainment's actual EPS was $-0.18, reflecting a 30.77% increase.</li>
<li>Despite market projections of an EPS of $0.21, Golden Entertainment's earnings on August 08, 2024 fell short with an actual EPS of $0.02, representing a -90.48% decrease from expectations.</li>
<li>The latest earnings announcement from Inspired Entertainment on August 08, 2024 exceeded expectations, with an actual EPS of $0.2 compared to the market's estimate of $0.1, resulting in a 100.0% increase.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>October 24, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">1.52</td>
<td>10.14%</td>
<td>$64.31</td>
<td>$69.96</td>
<td>8.79%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.26</td>
<td style="text-align: right;">-0.18</td>
<td>30.77%</td>
<td>$18.72</td>
<td>$18.83</td>
<td>0.59%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: right;">0.02</td>
<td>-90.48%</td>
<td>$28.12</td>
<td>$27.42</td>
<td>-2.49%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.10</td>
<td style="text-align: right;">0.20</td>
<td>100.0%</td>
<td>$8.48</td>
<td>$8.39</td>
<td>-1.06%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
Here's a comparison table presenting estimated and announced revenue figures for Boyd Gaming's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>912.95M</td>
<td>961.25M</td>
<td>5.29%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>1.66B</td>
<td>1.66B</td>
<td>0.18%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>174.60M</td>
<td>167.33M</td>
<td>-4.16%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>74.41M</td>
<td>75.60M</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Boyd Gaming <a href="https://www.benzinga.com/quote/BYD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Boyd Gaming Earnings Review: Q3 Summary

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent.

MITT

AG Mortgage Investment Q3 2024 Adj EPS $0.17 Beats $0.16 Estimate

NXPI

NXP Semiconductors shares are trading lower after the company issued soft guidance.

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

PLTR

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Upgrades

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) affirms FY2024 sales outlook from $65.00 million-67.00 million to $65.00 million-67.00 million.

Sophia Genetics Affirms FY2024 Sales Guidance to $65.00M-67.00M  VS Est. 65.66M

Biotech

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.47 by 0.68 percent. This is a 14.73 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.619 billion which beat the analyst consensus estimate of $4.566 billion by 1.16 percent. This is a 12.93 percent increase over sales of $4.090 billion the same period last year.

Emerson Electric Q4 2024 Adj. EPS $1.48 Beats $1.47 Estimate, Sales $4.619B Beat $4.566B Estimate

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $2.21 by 36.2 percent. The company reported quarterly sales of $3.117 billion which missed the analyst consensus estimate of $3.305 billion by 5.69 percent. This is a 0.06 percent increase over sales of $3.115 billion the same period last year.

Westlake Q3 2024 Adj. EPS $1.41 Misses $2.21 Estimate, Sales $3.117B Miss $3.305B Estimate

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.97 by 50.76 percent. This is a 52.91 percent decrease over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.06 billion by 3.82 percent. This is a 1.50 percent increase over sales of $1.00 billion the same period last year.

Hyster Yale Q3 2024 GAAP EPS $0.97 Misses $1.97 Estimate, Sales $1.02B Miss $1.06B Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

JMP Securities analyst Jonathan Wolleben initiated coverage with a Buy rating on Skye Bioscience (SKYE – Research Report) today and set a price tar...

JMP Securities Initiates a Buy Rating on Skye Bioscience (SKYE)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/10/2024, According to Top Analysts

Skye Bioscience (SKYE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on September 20. Analyst Jonathan W...

Buy Rating Affirmed for Skye Bioscience as Nimacimab Shows Competitive Edge in Obesity Drug Market

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Skye Bioscience (SKYE – Research Report), with a price target of ...

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on Skye Bioscience (SKYE – Research Report), with a price target ...

Craig-Hallum Sticks to Its Buy Rating for Skye Bioscience (SKYE)

Skye stock rallies 22% following weight-loss drug update

Skye Bioscience ( ($SKYE) ) just unveiled an announcement. Skye Bioscience, Inc. held a special meeting where stockholders approved an amendment to...

Skye Bioscience Approves Incentive Plan Amendments and Leadership Changes

Skye Bioscience ( ($SKYE) ) just unveiled an announcement. Skye Bioscience has announced the appointment of Paul Grayson as the new Chairman of the...

Skye Bioscience Appoints New Chairman for Strategic Growth

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, an acquisi...

Rising High: Compass Pathways reports Q3 earnings

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye's CB1-inhibiting antibody, nimacimab, achieved si...

Skye Bioscience announces preliminary data from diet-induced obesity model

CANN

CMPS

CRON

CVSI

FFNTF

GPCR

GTBIF

RBRK

RLAY

SHFS

SKYE

TCNNF

TLRY

VKTX

VREOF

Legal

Press Releases

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Management

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Comments

Skye Bioscience

Notizie

Ultime notizie per Skye Bioscience (NASDAQ:SKYE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO